Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Randall Fitzpatrick

Principal, Oliver Wyman Actuarial Consulting

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

Here’s more on how proposed modifications to CMS’ Advance Notice Summary may affect reimbursement, payment growth rates, and regulation.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

New analysis projects how MA plans would fare under new Part C benchmark formula.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

According to a new report from the Oliver Wyman Actuarial Practice, MA organizations can expect a drop in revenue next year.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting